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Summary
Neutralizing antibodies (NAb) against interferon-b
(IFN-b) develop in about a third of treated multiple
sclerosis patients and are believed to reduce therapeutic
ef®cacy of IFN-b on clinical and MRI measures. The
expression of the interferon acute-response protein,
myxovirus resistance protein A (MxA) is a sensitive
measure of the biological activity of therapeutically
applied IFN-b and of its reduced bioavailability due to
NAb. However, MxA may not be operative in the
pathogenesis of multiple sclerosis or the therapeutic
effect of IFN-b. Instead, matrix metalloproteinases
(MMPs) are increased in brain tissue, CSF and blood
circulation of multiple sclerosis patients and function as
effector molecules in several steps of multiple sclerosis
pathogenesis. One of the molecular mechanisms by
which IFN-b exerts its bene®cial effect in multiple
sclerosis is reduction of MMP-9 expression and increase
of its endogenous tissue inhibitor, TIMP-1. Quantitative
PCR measurements of MMP-2 and MMP-9, TIMP-1
and TIMP-2, and MxA were performed in peripheral
mononuclear cells from clinically stable multiple
sclerosis patients with relapsing remitting disease course
after short-term and long-term treatment with IFN-b.
IFN-b therapy down-regulated the expression of
MMP-9 and abolished that of MMP-2 in long-term, but
not short-term treated multiple sclerosis, while levels of
MxA were increased in both instances. The presence of
NAb reversed these effects, i.e. led to reduced MxA and
increased MMP-2/MMP-9 expression levels compared
with NAb± patients. In contrast, expression of TIMPs in
peripheral blood mononuclear cells remained unaffected
by IFN-b therapy and the presence of NAb. While MxA
is able to detect the biological action and reduced bio-
availability of IFN-b on the basis of single injections,
only MMP-9 shows quantitative correlation with the
NAb titre. Together with evidence that an imbalance
between MMP and TIMP expression is a crucial patho-
genetic feature in multiple sclerosis, these ®ndings
support the concept of a signi®cant role of NAb in
reducing the therapeutic ef®cacy of IFN-b.
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Introduction
Interferon-b (IFN-b) is the ®rst drug established as an
effective treatment for patients with relapsing remitting (RR)
and secondary progressive (SP) multiple sclerosis (IFNB
Multiple Sclerosis Study Group and University of British
Columbia Multiple Sclerosis/MRI Analysis Group, 1995;
Jacobs et al., 1996; European Study Group on Interferon b-1b
in Secondary Progressive Multiple Sclerosis, 1998; PRISMS
Study Group and University of British Columbia Multiple
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Sclerosis/MRI Analysis Group, 2001). As IFN-b does not
restore pre-existing structural damage and functional impair-
ment, but rather acts by attenuating damaging effects of
in¯ammatory processes, continuous administration is re-
quired to maintain therapeutic effects. Such long-term
therapy leads to the development of binding antibodies
(BAb) and neutralizing antibodies (NAb) in up to 80% of
patients (for a review, see Giovannoni et al., 2002). A number
of reports have addressed the biological signi®cance of the
latter on clinical and MRI measures; most of these suggest
decreased treatment ef®cacy of IFN-b (IFNB Multiple
Sclerosis Study Group and University of British Columbia
Multiple Sclerosis/MRI Analysis Group, 1996; Rudick et al.,
1998; PRISMS Study Group and University of British
Columbia Multiple Sclerosis/MRI Analysis Group, 2001;
Polman et al., 2003). Interferon-induced proteins such as
neopterin, b2-microglobulin, 2¢-5¢ oligoadenylate synthetase
and myxovirus resistance proteins (MxA and MxB) show an
acute up-regulation after IFN-injection and can serve as a
measure of its biological activity (Chiang et al., 1993; Witt
et al., 1993; Williams et al., 1998). Persistent NAb were
shown to attenuate the induction of MxA on the protein
(Deisenhammer et al., 1999; Vallittu et al., 2002) and
transcriptional level (Bertolotto et al., 2003) in peripheral
blood mononuclear cells (PBMC) from multiple sclerosis
patients.
Matrix metalloproteinases (MMPs) are a family of Zn2+-
dependent endoproteinases that act as effector molecules in
several steps of multiple sclerosis pathogenesis (for a review,
see Kieseier et al., 1999; Leppert et al., 2001). The subfamily
of gelatinases (MMP-2 and MMP-9) mediates the opening of
the blood±brain±barrier and the extravasation of immune
cells into the brain parenchyma in animal and in vitro models
(Gijbels et al., 1994; Leppert et al., 1996; StuÈve et al., 1996).
Other features of MMPs related to multiple sclerosis
pathogenesis are their ability to regulate the activity of
several cytokines and their receptors, and of adhesion
molecules (SchoÈnbeck et al., 1998; for a review, see
Leppert et al., 2001) and to lyse myelin components thus
contributing to epitope spreading through the release of
immunogenic degradation products (Proost et al., 1993). In
relapsing remitting (RR) and secondary progressive (SP)
multiple sclerosis, levels of MMP-9 are permanently
increased in brain tissue, CSF and serum (Leppert et al.,
1998; Lee et al., 1999; Lindberg et al., 2001; Waubant et al.,
1999, 2003). IFN-b decreases the transcriptional and protein
expression of MMP-2 and MMP-9 in T-cells and monocytic
cells, with the functional effect of reduced capacity to cross a
model blood±brain±barrier (Leppert et al., 1996; StuÈve et al.,
1996; Galboiz et al., 2001, 2002; Schmidt et al., 2001;
Nelissen et al., 2002). In multiple sclerosis patients, IFN-b
therapy down-regulates increased serum levels of MMP-9
and increases those of its endogenous tissue inhibitor TIMP-1
(Waubant et al., 1999, 2003), thus correcting excessive
proteolytic activity as a molecular mechanism of its thera-
peutic effect. In return, we hypothesized that reduced
bioavailability of IFN-b due to NAb may not only result in
decreased MxA synthesis, but also in attenuation of IFN-b
mediated suppression of MMP-2 and MMP-9.
The purpose of this study was to: (i) test for the effect of
short-term (12 h after injection) and long-term (>3 months)
treatment of IFN-b on the transcriptional regulation of MMP-
2 and MMP-9, and their respective endogenous inhibitors
TIMP-2 and TIMP-1; (ii) determine whether the occurrence
of NAb affects expression levels of MMPs/TIMPs; and
(iii) correlate the expression of MMPs/TIMPs with those of
MxA and NAb titres.
Methods
Patients and control subjects
This study was approved by the Regional Ethical Committee of
Piedmont. Informed consent was obtained from each patient before
beginning the study.
One hundred and four clinically stable patients (70 females, 34
males) with de®nite RR multiple sclerosis according to the
McDonald criteria (McDonald et al., 2001) were retrospectively
included in this study. Thirty-nine patients had never been treated
with IFN-b before entering this study (treatment-naive patients)
and 65 patients (long-term treated patients) were on treatment
with recombinant IFN-b [11 patients were treated with 30 mg
intramuscular (im) IFN-b1a (Avonexâ) (Biogen; Cambridge, MA,
USA) once a week (IFN-b1aim); 47 were treated with IFN-b1a
(Rebifâ) (Serono, Geneva, Switzerland), either with 22 mg (n = 31)
or 44 mg (n = 16) subcutaneous (sc) three times a week (IFN-b1asc);
and seven had been treated with IFN-b1b (Betaferonâ)
(Schering; Berlin, Germany) for at least 3 months (mean 6
SD = 24 6 20 months, range 3±84)]. Of the treatment-naive
patients, 16 received IFN-b1aim, 10 IFN-b1asc22mg, eight IFN-
b1asc44mg and ®ve IFN-b1b.
The expanded disability status scale (EDSS) score ranged from 0
to 6 points (mean 6 SD = 2 6 1.4). Patients had: (i) no
immunosuppressive drug therapy; (ii) no switch of IFN-b type;
and (iii) no glucocorticosteroid therapy <30 days prior to study. The
control group included 23 healthy volunteers (13 females, 10 males)
who did not display symptoms of viral infection at least 2 weeks
before and after blood donation.
NAb evaluation
Both long-term treated and treatment-naive patients were evaluated
for the presence of NAb at study entry (baseline). In long-term
treated patients, longitudinal measurements of NAb were performed
in serum samples collected at least 36 h after the last IFN-b injection
every 3 months until gene expression analysis. However, the last
NAb measurement and gene expression analysis were made from the
same blood sample, i.e. 12 h after the last injection. NAb were
measured with the cytopathic effect (CPE) assay as previously
described (Bertolotto et al., 2003); to insure maximal ligation with
presumed NAb, measurements were performed with the same type
of IFN-b as used in individual patients for therapy (Antonelli et al.,
1998). Brie¯y, a mean concentration of 7 3 104 cells in DMEM
medium 2% FCS (1 : 2.5 up to 1 : 5120) per 100 ml of the human
lung carcinoma cell line A549 (ECACC, Salisbury, UK) were plated
on 96-¯at well tissue culture plates and incubated overnight to form a
con¯uent monolayer. Serum samples were diluted (1:2.5 up to
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1:5120), mixed with one of the three IFN-b preparations to a ®nal
concentration of 10 IU/ml, and then incubated for 1 h. Serum-IFN-b
mixture (100 ml) was then incubated with A549 cells for 24 h. Cells
were then infected with the cytopathic encephalomyocarditis murine
virus at a concentration of 5±10 virus particles/cell. After 24 h
incubation, viable cells were ®xed and stained with crystal violet in
20% ethanol. Excess dye was eluted with 33% acetic acid and
absorbance was measured in a densitometer at 620 nm. Controls for
viral activity, cellular viability and titration of the IFN-b preparation
were run in parallel in each assay. According to World Health
Organization recommendations, data from neutralization assays are
reported as the reciprocal of the highest dilution of serum inducing
50% neutralization (i.e. neutralizing 10 U/ml of IFN activity to an
apparent 1 U/ml of activity). The neutralization titre of a serum
sample was calculated according to Kawade's formula (Kawade
et al., 1986) and expressed in laboratory units (LUs). A level of
>20LU is generally considered the threshold of positivity
(Bertolotto et al., 2003). Three categories of patients were identi®ed
based on the CPE assay: (i) patients in whom no NAb were detected
during the whole period of follow-up (NAb±); (ii) patients tested
positive for NAb in >2 consecutive samples were declared
persistent NAb+ (pNAb+); and (iii) patients who had single
positivity at the time point of gene expression analysis were
declared isolated NAb+ (iNAb+).
Gene expression analysis
In treatment-naive patients, blood samples were taken prior to the
®rst and after the second (7 days + 12 h) IFN-b injection (mean6SD
12.1 6 1.2 h, range 10±13 h). For long-term treated patients, blood
specimens were obtained 12.3 6 1.6 h (range 9±14 h) after the last
IFN-b injection. PBMC were separated from edetic anticoagulated
whole blood by Ficoll-Paque (Pharmacia; Uppsala, Sweden)
centrifugation and subjected to RNA extraction using RNAwiz,
following the manufacturer's instructions (Ambion; Austin, TX,
USA). Total RNA (50 ng/ml ®nal concentration) was ®rst incubated
with 0.5 mg of random hexamer at 70°C for 2 min and then reverse
transcribed at 37°C for 1 h in reaction mixture containing a ®nal
concentration of 500 mM of each deoxynucleotide triphosphate,
1 U/ml of Moloney murine leukaemia virus reverse transcriptase and
1 U/ml of RNAase inhibitor (RNAsin) (both from Promega
Corporation; Madison, WI, USA). cDNA was used as a template
for the real-time PCR analysis based on the 5¢-nuclease assay with
the ABI PRISMâ 7000 Sequence Detection System (Applied
Biosystems, PE Europe B.V., Rotkreuz, Switzerland). Real-time
PCR primers and probes were designed using primer-ExpressÔ
software (Applied Biosystems). Expression of MMP-2, MMP-9,
TIMP-1, TIMP-2 and MxA was analysed and transcriptional
expression was normalized using the housekeeping gene glycer-
aldehyde phosphate dehydrogenase (GAPDH) as reference in order
to avoid differences due to possible RNA degradation/contamination
or different reverse transcription ef®ciency. The relative expression
levels of targets were calculated by the comparative cycle threshold
(CT) method provided by Applied Biosystems. Targets were
considered detectable with CT values <40. Expression levels of
targets with CT values >35 were not described as relative expression,
due to the semi-quantitative character of CT values in this range.
Comparison of baseline expression levels of MxA in multiple
sclerosis treatment-naive patients and controls was performed using
competitive PCR results as previously described (Bertolotto et al.,
2003).
Statistical analysis
Primary data are expressed as median (range) unless otherwise
stated. Data were analysed using non-parametric statistical tests
except for the linear regression analysis of the correlation of
expression levels of MxA, MMP-9 and TIMP-1 as a function of
treatment duration. Spearman rank correlation of expression levels
between different genes, of intra-individual gene expression at
different time points, and of MxA/MMP-9 expression levels with
NAb titres were calculated. Expression levels of genes at different
time points or between different treatment regimens, and according
categorical differences of NAb status, were compared using the
Mann±Whitney U test. The incidence of NAb development was
compared between different treatment groups using the Fisher's
exact test. P values <0.05 were considered signi®cant.
Results
NAb status and treatment schemes
At baseline, both treatment-naive and long-term treated
patients scored negative for NAb (data not shown). In the
course of long-term IFN-b treatment, NAb were detectable in
26% (17 out of 65) of patients: 22% (14 out of 65) had pNAb+
and 3% (5 out of 65) had iNAb+ (at the time point of blood
sampling for gene expression analysis). Of the 17 long-term
IFN-b treated patients who had developed NAb at the time
point of gene expression analysis, four were treated with IFN-
b1b and 13 were treated with IFN-b1asc (22 mg/injection: 7
out of 13; 44 mg/injection: 6 out of 13), whereas no NAb were
detected in patients treated with IFN-b1aim. The duration of
treatment was signi®cantly longer with IFN-b1b [58 months
(15±73 months)] compared with the various types and
dosages of IFN-b1a [sc22: 20 months (3±84 months); sc44:
15 months (3±68 months): im: 18 months (5±60 months); all
P < 0.016], whereas the duration of treatment between the
three groups of patients who received IFN-b1a was not
statistically different (all P > 0.36).
Short-term effects of IFN-b injection on MxA
and MMP/TIMP gene expression
Figure 1A shows that low amounts of MxA [relative
expression compared with GAPDH: 0.08930 (0.02121±
2.29740)] are constitutively expressed in all multiple scler-
osis patients; the expression levels are similar to those in 23
healthy control subjects as measured by competitive PCR
(Bertolotto et al., 2003) (data not shown; P = 0.62). The
injection of IFN-b in treatment-naive patients led to a >20-
fold increase of median MxA expression [1.9185 (0.1756±
4.4840)] 12 h later (P < 0.0001). However, individual
changes were highly variable, i.e. baseline MxA expression
levels were not predictive for their degree of induction
(P = 0.99, r < 0.001). Three patients had exceptionally high
MxA levels at baseline who scored around the median value
observed after IFN-b injection; of these, one patient showed
no, and two others only a slight increase (1.4- and 1.8-fold,
respectively) of MxA mRNA on IFN-b injection (Fig. 2). A
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retrospective evaluation of case ®le histories of these patients
did not reveal indications of intercurrent viral infections or
other diseases, and the percentage of patients with such high
expression of MxA was similar to that found earlier
(Bertolotto et al., 2001, 2003). Transcripts for MMP-9
[0.0046 (0.0005±0.1756)], TIMP-1 [0.3220 (0.1713±
6.5889)] and TIMP-2 [0.0581 (0.0052±1.1728)] were present
in all treatment-naive patients (Fig. 3A,C and D). In contrast,
MMP-2 expression levels were not detectable in 18% (7 out
of 39) of samples and too low in the remainder for relative
expression to be quanti®ed. Therefore, MMP-2 expression
was quanti®ed on the basis of CT values only (Fig. 3B). Other
than for MxA, the transcriptional expression of MMP-2 and
MMP-9 and their respective inhibitors (TIMP-2 and TIMP-1)
did not show signi®cant acute phase changes after IFN-b
injection. The inducibility of MxA and MMP/TIMP expres-
sion did not differ after treatment with either types or dosage
of IFN-b (data not shown).
Long-term effects of IFN-b treatment on MxA
and MMP/TIMP gene expression
In long-term IFN-b treated, NAb± patients, the median MxA
expression level was more than 8-fold higher than the
baseline value [0.7341 LU (0.1373±4.9588LU), P < 0.0001]
(Fig. 1A), but less than a third compared with that observed
in treatment-naive patients after the second injection
(P < 0.0001). The attenuation of MxA up-regulation observed
here in the ®rst 3±6 months of chronic IFN-b treatment has
been demonstrated by others, both on the transcriptional and
the protein level (Vallittu et al., 2002; Gniadek et al., 2003).
Conversely, in the later course of IFN-b treatment (months 3±
84), MxA levels remained stable, i.e. they showed no change
as a function of treatment duration (Fig. 1B). In parallel, long-
term IFN-b therapy led to a 5-fold decrease of MMP-9
transcripts [0.0008 (not detectable±0.0146)] compared with
untreated patients (P < 0.0001) and was below detection limit
in 14.5% (7 out of 48) of samples (Fig. 3A). However, no
signi®cant correlation between MxA and MMP-9 expression
levels on an individual basis could be established (data not
shown).
The suppressive effect of IFN-b was even more pro-
nounced for MMP-2, where all 48 samples from NAb±
patients scored below detection threshold (P < 0.0001 for
comparison with treatment-naive patients at baseline)
(Fig. 3B). In contrast, transcriptional expression of both
TIMPs remained unchanged under long-term IFN-b
treatment (Fig. 3C and D).
Fig. 1 (A) Comparison of MxA mRNA levels in treatment-naive
patients before ®rst and after second injection, and long-term
IFN-b treated (®lled circles = pNAb+; open circles = iNAb+)
multiple sclerosis patients. Horizontal bars indicate medians.
(B) MxA RNA levels in NAb± (closed circles) and pNAb+ (open
circles) patients as a function of IFN-b treatment time. Results of
statistical evaluation of linear regression analysis for patients
without (straight line) and with (dashed line) NAb were
PNAb± = 0.30; r = 0.15 and PpNAb+ = 0.47; r = 0.22.
Fig. 2 Change of MxA expression levels in individual treatment-
naive patients as shown in Fig. 1A.
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To exclude the possibility of delayed pharmacodynamic
effects of IFN-b, expression levels of MMPs/TIMPs were
analysed as a function of time. As for MxA, transcriptional
expression of MMP-9 in NAb± patients was independent of
treatment duration (Fig. 4A). Hence, for both genes the effect
of long-term IFN-b therapy was established in the ®rst
3 months of treatment. Similarly, TIMP-1 (Fig. 4B) and
TIMP-2 (data not shown) expression levels remained stable
under long-term IFN-b therapy.
There was no difference between the various types and
dosages of IFN-b in up-regulating MxA expression (data not
shown). In contrast, suppression of MMP-9 expression was
less pronounced in patients treated with IFN-b1aim [0.0037
(not detectable±0.0146)] compared with those on IFN-b1b
[0.0004 (not detectable±0.0026)] (P = 0.049) or IFN-b1asc22
[0.0006 (not detectable±0.0047)] (P = 0.0012), while a
tendency for such a difference was seen for IFN-b1asc44
[0.0016 (not detectable±0.0099)] (P = 0.09). On the other
hand, differences in MMP-9 expression levels between the
two dosages of IFN-b1asc and IFN-b1b were not signi®cant
(data not shown). Accordingly, expression levels of TIMP-1
and TIMP-2 were independent of types and dosages of IFN-b.
Effects of NAb on MxA, MMP/TIMP
expression
Analysis strati®ed by NAb status
In long-term treated patients with NAb+ (pNAb+ and
iNAb+), median MxA expression levels were 3.13 [0.2384
(0.0177±2.8679)] lower than those of NAb± patients
(P < 0.0001) (Fig. 1A). However, two pNAb+ patients
showed MxA expression in the range of NAb± patients.
Although median MxA expression in NAb+ patients was still
Fig. 3 Comparison of (A) MMP-9, (B) MMP-2, (C) TIMP-1 and (D) TIMP-2 mRNA levels in treatment-naive and long-term IFN-b
treated (®lled circles = pNAb+; open circles = iNAb+) multiple sclerosis patients. Horizontal bars indicate medians of all patients per
group. Respective targets were considered not being detectable with CT values >40. Note that levels of MMP-2 (B) are depicted as a CT
value, as relative expression normalized with GAPDH is not quantitative with low expressions of the target gene.
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2.73 higher than in treatment-naive patients at baseline (T0),
the statistical comparison failed to show a signi®cant
difference between the two groups (P = 0.15). Accordingly,
the presence of NAb+ correlated with higher levels of MMP-
9 [0.00399 (not detectable±0.0829)] compared with NAb±
samples (P = 0.0184) and reached similar values as untreated
multiple sclerosis patients (P = 0.14) (Fig. 3A). Moreover,
MMP-2 was detectable in 24% (4 out of 17) NAb+ patients
compared with 0% in NAb± patients (P < 0.0001). However,
this number was still lower in untreated patients [82% (32 out
of 39)] (P = 0.0001) (Fig. 3B).
As for NAb± patients, pNAb+ did not change the
transcriptional expression of MxA (Fig. 1B), MMP-9
(Fig. 4A), TIMP-1 (Fig. 4B) and TIMP-2 (data not shown)
as a function of treatment duration or the types of IFN-b used
(data not shown). Such analysis was not possible for MMP-2
due to the lack of quantitative data.
Correlation of NAb titres with MxA and MMP-9
expression levels
Earlier work has shown that NAb titres <45 LU have variable
impact on the transcriptional expression of MxA, whereas
titres >45 LU led to a complete suppression as measured by
competitive PCR (Bertolotto et al., 2003). Accordingly, real-
time PCR used here demonstrates that in presence of NAb
(with the exception of two outliers), MxA levels ranged
around the median value of treatment-naive patients at
baseline and transcriptional induction by IFN-b was abro-
gated. Fig. 5A demonstrates that this effect occurs independ-
ently of the titre of NAb (be it above or below 45 LU). In
contrast, there is a tendency for a correlation of MMP-9
expression levels and the whole range of NAb titres
(P(n = 17) = 0.066; r = 0.46). Restricting the analysis to
titres >45LU this correlation becomes highly signi®cant
(P(n = 12) = 0.011, r = 0.77) (Fig. 5B).
Discussion
There is ongoing controversy about the impact of NAb
against IFN-b on its therapeutic effect in multiple sclerosis
(Giovannoni et al., 2002; Polman et al., 2003). In large
cohorts, up to a third of multiple sclerosis patients receiving
IFN-b develop NAb, mostly after 6±18 months of treatment.
Over 90% of those are reported to convert back to
seronegativity after 8.5 years of treatment (Rice et al.,
1999). However, the presence of NAb may be long lasting. In
NAb+ patients observed for up to 67 months of IFN-b
treatment, seroconversion is more likely to occur with NAb
titres <200 LU, whereas titres above this threshold are
associated with persistent seropositivity; in fact, 62% of
NAb+ patients remained seropositive during this time period
(Capobianco et al., 2003). In the PRISMS-4 trial (IFN-b1asc),
negative effects of NAb on clinical parameters were not
obvious during the ®rst 2 years of treatment whereas, after
4 years, NAb+ patients had a 62% higher per year relapse rate
and an almost 53 higher increase in T2 lesion load in MRI
(PRISMS Study Group and University of British Columbia
Multiple Sclerosis/MRI Analysis Group, 2001). Similar
results were observed with IFN-b1b (Polman et al., 2003)
and IFN-b1aim (Rudick et al., 1998) on these measures.
The current standard method to determine NAb in serum is
indirect, i.e. via their in vitro capacity to antagonise the
antiviral activity of IFN-b in a CPE assay. This test is
technically dif®cult and there is no industrial standard with
regard to the de®nition of seropositivity per se (detection of
NAb in a single versus two consecutive samples) and the cut
off level of titre considered biologically relevant (Giovannoni
Fig. 4 (A) MMP-9, (B) TIMP-1 RNA levels in NAb± (®lled
circles) and NAb+ (open circles) patients in function of IFN-b
treatment time. For calculation of regression analysis, values for
MMP-9 (see Fig. 3A) below the detection threshold were not
counted. Results of statistical evaluation of linear regression
analysis for patients without (straight line) and with (dashed line)
NAb were PNAb± = 0.91; r = 0.016 and PpNAb+ = 0.62; r = 0.146
for MMP-9, and PNAb± = 0.055; r = 0.279 and PpNAb+ = 0.79;
r = 0.077 for TIMP-1. Note different scale of y-axis for respective
targets.
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et al., 2002). The measurement of transcriptional or protein
expression of IFN acute-response proteins such as neopterin,
b-2-microglobulin and Mx proteins offers an alternative
measure for IFN-b bioavailability which overcomes some of
the disadvantages of the CPE assay (Vallittu et al., 2002;
Bertolotto et al., 2003). However, there is no evidence for a
functional role of these molecules in multiple sclerosis and
data showing a direct correlation of acute-response protein
induction by IFN-b with the long-term clinical course of
multiple sclerosis patients with or without NAb has been
published. Instead, MMPs are pre-eminent effector molecules
in several crucial steps of multiple sclerosis pathogenesis
(Kieseier et al., 1999; Leppert et al., 2001). A speci®c feature
of multiple sclerosis, as opposed to other neuro-in¯ammatory
disorders such as infectious meningitis (Leppert et al., 2001),
is the induction of MMPs in the CNS and the peripheral blood
circulation without compensatory up-regulation of their
endogenous tissue inhibitors, TIMPs, leading to a persistent
imbalance towards excessive proteolytic activity (Lee et al.,
1999; Waubant et al., 1999, 2003; Lindberg et al., 2001).
Moreover, intercurrent increase of MMP-9, or of the MMP-9/
TIMP-1 ratio in serum of RR and SP multiple sclerosis
predicts upcoming subclinical disease activity as detected by
the development of new gadolinium-enhancing lesions in
MRI (Waubant et al., 1999, 2003). There is accumulating
evidence that a large part of the bene®cial effect of IFN-b in
multiple sclerosis results from its capacity to suppress the
expression of MMPs (for a review, see Yong et al., 2002) and,
in parallel, to up-regulate TIMP-1 (Waubant et al., 1999,
2003). Interestingly, the pathophysiological link between
MMPs and IFN-b in multiple sclerosis is not unidirectional. A
recent study demonstrated that MMP-9 exerts proteolytic
activity on IFN-b; thus the inherently increased concentra-
tions of MMP-9 in serum, CSF and brain tissue of multiple
sclerosis patients destroy the bioactivity of endogenous and
therapeutically administrated IFN-b (Nelissen et al., 2003).
Here we show that IFN-b leads to an inverse transcriptional
regulation of MxA and of MMP-2 and MMP-9 in RR multiple
sclerosis patients. Conversely, the presence of NAb against
IFN-b are associated with an attenuated induction of MxA
and reduced suppression of MMPs. Based on these results, we
propose increased MMP activity as one mechanism by which
NAb abrogate the effect of IFN-b in multiple sclerosis. The
response patterns of MxA and MMP-9 differ considerably;
MxA is very sensitive to detect decreased bioavailability of
IFN-b due to NAb on the basis of single measurements after a
single injection, but lacks a dynamic response in function of
NAb titres. This agrees with the results of other studies where
no correlation of NAb titres with expression levels of MxA
(Deisenhammer et al., 1999; Bertolotto et al., 2003) or with
other IFN acute-response proteins (neopterin, b2-micro-
globulin) (Rudick et al., 1998) was demonstrated. On the
other hand, the ®nding that NAb titres correlate positively
with MMP-9 expression suggests that the quantitative extent
of the immune response of multiple sclerosis patient against
therapeutically applied IFN-b may be of biological relevance.
With the caveat that treatment groups were not randomized
and had different treatment durations, quantitative differences
of MMP-9 suppression in NAb± patients suggest that IFN-
b1asc and IFN-b1b exert a slightly higher biological activity
compared with IFN-b1aim. Although the kinetics of MMP-9
suppression by the various preparations of IFN-b are not
known, it is conceivable that the higher total amount or the
shorter dosage intervals of the former types of IFN-b may be
responsible for this result. It is unclear, however, whether
these differences are clinically relevant, vis-aÁ-vis the fact that
the less suppressive activity of IFN-b1aim may be counter-
balanced by a far lower incidence of NAb induction observed
in all therapeutic trials with the current formulation (for a
review, see Giovannoni et al., 2002) and in longitudinal
comparisons between the different types of IFN-b (Bertolotto
et al., 2002), as well as in the present study cohort.
Fig. 5 Correlation of NAb titres with expression levels of MxA (A)
and MMP-9 (B) in patients positive for NAb (®lled circles =
pNAb+; open circles = iNAb+) at the time point of gene
expression analysis. For MMP-9 and NAb titres, statistical
evaluation of correlation resulted in P(n=17) = 0.066; r = 0.46 (all
patients) and P(n = 12) = 0.011; r = 0.77 (patients with titres
>45LU), respectively.
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At ®rst glance, the present ®ndings seem to partly
contradict earlier work where IFN-b was shown to increase
serum protein levels of TIMP-1 after 4 months of treatment
(Waubant et al., 2003). Moreover, high amounts of MMP-2
are constitutively expressed in CSF and serum, and are widely
believed not to vary in the course of multiple sclerosis,
speci®cally during IFN-b therapy (Trojano et al., 1999;
Waubant et al., 2003). However, protein levels in serum are
representative of contributions from various cellular com-
partments, whereas mRNA measurements as used here allow
the quanti®cation of gene usage in a speci®c cell type.
Besides PBMC, endothelial cells and other cells of the
vascular lining contribute to the production of MMPs and
TIMPs (Bugno et al., 1999; Nelissen et al., 2002; Taraboletti
et al., 2002). Quantitatively, leukocytes produce predomin-
antly MMP-9, while the amounts of MMP-2 are relatively
scarce as shown for transcripts (present results), as well as in
the protein level in PBMC (Johnatty et al., 1997), and may be
absent in resting T-cells (Leppert et al., 1996) and monocytes
(Xie et al., 1994). In contrast, endothelial cells produce
predominantly MMP-2, representing probably the predomin-
ant source in serum, while they contribute only little MMP-9
(Nelissen et al., 2002). Thus, quantitatively subtle up-
regulation of MMP-2 expression in the PBMC compartment
of multiple sclerosis patients may easily escape detection in
serum measurements. Conversely, IFN-b treatment ef®-
ciently reduces MMP-2 transcription in PBMC of multiple
sclerosis patients as observed here and by others (Galboiz
et al., 2001); this is further corroborated by the changes on the
protein level in experimental autoimmune encephalitis
(Schmidt et al., 2001), and in vitro (Leppert et al., 1996).
Along with present results, others have found that mRNA
levels of TIMP-1 and TIMP-2 from PBMC of IFN-b treated
multiple sclerosis patients are unchanged or rather decreased,
respectively (Lichtinghagen et al., 1999; Galboiz et al.,
2001). We therefore conclude that the up-regulation of TIMP-
1 protein in serum of IFN-b treated patients does not originate
from PBMC, but derives most probably from endothelial
cells. IFN-b does not modulate expression of MMP-2 and
MMP-9 in endothelial cells (Nelissen et al., 2002) in vitro,
but the effects on TIMP-1 regulation and the impact of NAb
have not so far been investigated. However, there is indirect
and partial evidence that IFN-b up-regulates TIMP-1 pro-
duction in endothelial cells. In multiple sclerosis patients, the
decreased production of the anti-in¯ammatory cytokine IL-10
by PBMC is corrected by IFN-b (Chabot et al., 2000; Ozenci
et al., 2000), and this cytokine increases the production of
TIMP-1 and decreases that of MMP-2 and MMP-9 in
endothelial cells (Stearns et al., 1999).
Our study has some obvious limitations, as it was not
designed to investigate whether NAb-induced changes of
MxA and MMPs relate to decreased therapeutic effect of
IFN-b and, hence, a more severe clinical course. Secondly,
the interpretation of single measurements of these markers in
individual patients may be of little value considering the wide
range of expression levels and the overlap with NAb±
patients. A small study, which attempted to delineate the
impact of NAb on the protein levels of MMP-9 (Trojano et al.,
1999), showed that pNAb+ multiple sclerosis patients had
higher MMP-9 serum levels during an observation time of 6±
18 months of IFN-b therapy and a greater increase of clinical
disability as measured by Expanded Disability Status Score
compared with NAb± patients. However, the NAb+ cohort
consisted of only ®ve patients and MMP-9 measurements
were performed by semi-quantitative zymography, which
detects only selected species of MMP-9 (TIMP-1-free, pro-
and active MMP-9). Moreover, increased MMP-9 expression
in IFN-b treated multiple sclerosis patients is not speci®c for
the presence of NAb, but has also been observed immediately
before and during the occurrence of new gadolinium-
enhancing lesions (Waubant et al., 2003). Such increased
subclinical disease activity may explain why, in some
patients, IFN-b treatment was not effective in lowering
MMP-9 expression levels compared with controls, despite the
absence of NAb. This could also be the case for MxA, as high
expression levels due to intercurrent viral infection could
interfere with the suppression by NAb activity. Hence, the
simultaneous measurement of both targets in a longitudinal
manner may be compulsory for a meaningful interpretation of
NAb titres for clinical diagnostic purposes. Prospective
studies are needed to determine whether measurements of
MMPs, in combination with MxA and other IFN-response
proteins, would provide a statistically robust array of markers
to allow predicting the degree of clinical response to IFN-b
on an individual basis, and to indicate decreased treatment
effect due to NAb.
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